These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29154019)

  • 41. Efficacy of Direct-acting Antivirals to Improve Clinical Condition, Fibrosis, and Liver Function in Liver Transplant Recipients Infected by Hepatitis C.
    Garcia-Pajares F; Tejedor-Tejada J; Torres-Yuste R; Almohalla-Alvárez C; Sánchez-Ocaña R; Peñas-Herrero I; Cimavilla-Román M; de Benito-Sanz M; Sánchez-Martín F; Sánchez-Antolín G
    Transplant Proc; 2019; 51(1):74-76. PubMed ID: 30655151
    [TBL] [Abstract][Full Text] [Related]  

  • 42. INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION?
    Andrade VG; Yamashiro FDS; Oliveira CV; Kurozawa LL; Moreira A; Silva GF
    Arq Gastroenterol; 2018; 55(2):184-187. PubMed ID: 30043871
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.
    Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study
    Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
    Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
    Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals.
    Yoh K; Nishikawa H; Enomoto H; Ishii A; Iwata Y; Miyamoto Y; Ishii N; Yuri Y; Hasegawa K; Nakano C; Nishimura T; Aizawa N; Sakai Y; Ikeda N; Takashima T; Takata R; Iijima H; Nishiguchi S
    Nutrients; 2017 Oct; 9(10):. PubMed ID: 29057827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study.
    Ippolito AM; Milella M; Messina V; Conti F; Cozzolongo R; Morisco F; Brancaccio G; Barone M; Santantonio T; Masetti C; Tundo P; Smedile A; Carretta V; Gatti P; Termite AP; Valvano MR; Bruno G; Fabrizio C; Andreone P; Zappimbulso M; Gaeta GB; Napoli N; Fontanella L; Lauletta G; Cuccorese G; Metrangolo A; Francavilla R; Ciracì E; Rizzo S; Andriulli A
    Dig Liver Dis; 2017 Sep; 49(9):1022-1028. PubMed ID: 28487083
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
    Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
    Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis.
    Yamamoto H; Ikesue H; Ikemura M; Miura R; Fujita K; Chung H; Suginoshita Y; Inokuma T; Hashida T
    J Pharm Health Care Sci; 2018; 4():17. PubMed ID: 30026959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021.
    Du X; Mi J; Cheng H; Song Y; Li Y; Sun J; Chan P; Chen Z; Luo S
    Infect Dis Poverty; 2023 Mar; 12(1):28. PubMed ID: 36978198
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative effectiveness of pharmacist care delivery models for hepatitis C clinics.
    Naidjate SS; Zullo AR; Dapaah-Afriyie R; Hersey ML; Marshall BDL; Winkler RM; Berard-Collins C
    Am J Health Syst Pharm; 2019 May; 76(10):646-653. PubMed ID: 30873537
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient perspectives and use of copayment assistance during the COVID-19 pandemic.
    Wong WB; Jinnett K
    J Manag Care Spec Pharm; 2023 Jan; 29(1):17-23. PubMed ID: 35481416
    [No Abstract]   [Full Text] [Related]  

  • 53. Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
    Pischke S; Polywka S; Proske VM; Lang M; Jordan S; Nashan B; Lohse AW; Sterneck M
    Transpl Infect Dis; 2016 Feb; 18(1):141-5. PubMed ID: 26485543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals.
    Campos Fernández de Sevilla MÁ; Gallego Úbeda M; Heredia Benito M; García-Cabrera E; Monje García B; Tovar Pozo M; Delgado Téllez de Cepeda L; Iglesias-Peinado I
    Int J Clin Pharm; 2019 Apr; 41(2):488-495. PubMed ID: 31028599
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal.
    Weigert A; Querido S; Carvalho L; Lebre L; Chagas C; Matias P; Birne R; Nascimento C; Jorge C; Adragão T; Bruges M; Machado D
    Transplant Proc; 2018 Apr; 50(3):743-745. PubMed ID: 29661427
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017.
    Spradling PR; Xing J; Rupp LB; Moorman AC; Gordon SC; Lu M; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Holmberg SD;
    J Clin Gastroenterol; 2021 Jan; 55(1):77-83. PubMed ID: 32250999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis C treatment in the era of directly acting antivirals: an encouraging scenario.
    Jain M
    Trop Doct; 2020 Oct; 50(4):334-336. PubMed ID: 32631174
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of specialty pharmacy on telaprevir-containing 3-drug hepatitis C regimen persistence.
    Henderson RR; Visaria J; Bridges GG; Dorholt M; Levin RJ; Frazee SG
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1227-34. PubMed ID: 25443516
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network.
    Morris L; Smirnov A; Kvassay A; Leslie E; Kavanagh R; Alexander N; Davey G; Williams O; Gilks C; Najman J
    Int J Drug Policy; 2017 Sep; 47():216-220. PubMed ID: 28666635
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
    Mashiba T; Joko K; Kurosaki M; Ochi H; Osaki Y; Kojima Y; Nakata R; Goto T; Takehiro A; Kimura H; Mitsuda A; Kawanami C; Uchida Y; Ogawa C; Kusakabe A; Narita R; Ide Y; Abe T; Tsuji K; Kitamura T; Okada K; Sohda T; Shigeno M; Satou T; Izumi N
    PLoS One; 2018; 13(4):e0194704. PubMed ID: 29659591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.